Inactive Instrument

News Cortex Pharmaceuticals OTC Bulletin Board

Equities

US2205243007

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

04-10	RespireRx Pharmaceuticals Inc. announced that it has received $0.1 million in funding	CI
03-20	RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury	05-29	AQ
RespireRx Pharmaceuticals Inc. announced that it has received $0.1 million in funding	04-09	CI
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury	03-20	AQ
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury	03-20	CI
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine	02-13	AQ
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for Their Non-Opioid Lead GABAkine	02-13	CI
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors	01-22	AQ
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dariusz Naziek to its Board of Directors	01-22	CI
RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient	01-04	AQ
Respirerx Pharmaceuticals Inc. Announces the Publication of A Case Report in Which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient	01-04	CI
RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development	12-11	AQ
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-17	CI
Today's Top OTC Stocks Watchlist (SWISF, EPAZ, ABQQ, RSPI)	23-10-13	AQ
RespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services	23-10-12	AQ
RespireRx Pharmaceuticals : SETTLEMENT AND EXCHANGE AGREEMENT - Form 8-K	23-10-02	PU
Attention Deficit Hyperactivity Disorder Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)	23-09-26	AQ
RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
CapitalGainsReport: Sub Penny Stocks Set To Soar: EPAZ, RSPI, TPTW, HGEN	23-08-10	AQ
RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company	23-08-09	AQ
RespireRx Pharmaceuticals : Cortex Pharmaceuticals, Inc. 2014 Equity, Equity-Linked and Equity Derivative Plan - Form 8-K	23-06-13	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cortex Pharmaceuticals OTC Bulletin Board

Equities

US2205243007

Summary

Filters